|

225Ac-ETN029 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Novartis Pharmaceuticals1

Indications

  • Gastroenteropancreatic Neuroendocrine Carcinoma1
  • Neuroendocrine Prostate Cancer1
  • Large Cell Neuroendocrine Carcinoma of the Lung1
  • Small Cell Lung Carcinoma1
  • Lung Cancer1

Iowa City, Iowa1 trial

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

University Of Iowa

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.